-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 23, 2021, AstraZeneca announced that the U.
Since the mid-1990s, the incidence of type 2 diabetes has been increasing among children and adolescents
In October 2017, the FDA approved Exenatide as a single-dose automatic injection device administered once a week for the treatment of adult patients with type 2 diabetes
This approval is supported by the results of a 24-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial called BCB114
In terms of safety, the safety and tolerability characteristics observed in the trial are similar to those observed in adults
Reference materials:
[1] BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older.